BRAF and melanoma: In a pooled analysis from the International Neoadjuvant Melanoma Consortium of six clinical trials of anti-PD-1-based ICB or BRAF/MEK-targeted therapy, here pathologic complete response (pCR) correlated with improved recurrence-free survival (2-year RFS with pCR 89% vs. no pCR 50%, p < 0.001) and OS (2-year pCR OS 95% vs. no pCR 83%, p = 0.027).